Cencora Q4 adj EPS $3.84 (+15%); revenue $83.7B; raises dividend 9%; new segment structure

Cencora, Inc.

2025-FY EPS reported $7.96 revenue$321,332,819,000

Q4 GAAP diluted EPS $(1.75) (prior yr $0.02); adjusted EPS $3.84 (+15% YoY); revenue $83.7B (+5.9%).
FY2025 revenue $321.3B (+9.3%); GAAP EPS $7.96; adjusted EPS $16.00 (+16.3%).
Quarterly dividend increased 9%; long-term guidance raised.
New reporting structure Q1 FY26: U.S. Healthcare Solutions, Intl Healthcare Solutions, Other (under strategic review: MWI, Profarma, U.S. Consulting).
U.S. Healthcare Solutions FY2025 op income $3.28B (1.15% margin); Intl Healthcare op income $588M (2.07%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.